NIKKEI 225
38,202.37 -632.73 (-1.63%) HANG SENG
18,313.86 -165.51 (-0.90%) CRUDE OIL
78.98 +0.60 (+0.77%) GOLD FUTURES
2,320.30 -3.90 (-0.17%) DOW
39,040.78 +156.52 (+0.40%) Bitcoin GBP
50,181.68 -332.33 (-0.66%)
Avadel Pharmaceuticals plc (AVDL)
| Previous close | 18.18 |
| Open | 15.78 |
| Bid | 16.73 x 100 |
| Ask | 16.83 x 200 |
| Day's range | 15.65 - 17.85 |
| 52-week range | 9.50 - 19.09 |
| Volume | |
| Avg. volume | 1,213,378 |
| Market cap | 3.131B |
| Beta (5Y monthly) | 1.63 |
| PE ratio (TTM) | N/A |
| EPS (TTM) | -2.00 |
| Earnings date | 08 May 2024 |
| Forward dividend & yield | N/A (N/A) |
| Ex-dividend date | N/A |
| 1y target est | 23.10 |
GuruFocus.comAvadel Pharmaceuticals Reports First Quarter 2024 Earnings: Revenue Surpasses Estimates but Net ...
Insight into Avadel Pharmaceuticals' Q1 Financial Performance and Strategic Updates
GlobeNewswireAvadel Pharmaceuticals Provides Corporate Update and Reports First Quarter 2024 Financial Results
-- Generated $27.2 million in net revenue from sales of LUMRYZ™ -- -- Through March 31, greater than 2,800 patients enrolled in Avadel’s RYZUP patient support services and more than 1,700 patients initiated therapy -- -- Pursuing expansion opportunities for LUMRYZ with sNDA in pediatric narcolepsy; on track to enroll first patient in a Phase 3 pivotal idiopathic hypersomnia trial in the second half of 2024 -- -- Management to host a conference call today at 8:30 a.m. ET -- DUBLIN, Ireland, May 0
- GlobeNewswire
Avadel Pharmaceuticals to Provide a Corporate Update and Report First Quarter 2024 Financial Results on May 8
DUBLIN, Ireland, May 01, 2024 (GLOBE NEWSWIRE) -- Avadel Pharmaceuticals plc (Nasdaq: AVDL), a biopharmaceutical company focused on transforming medicines to transform lives, announced today that it will host a conference call and live webcast at 8:30 a.m. ET on Wednesday, May 8, 2024, to provide a corporate update and discuss the Company's financial results for the first quarter ended March 31, 2024. To access the conference call, investors are invited to dial +1 (800) 715-9871 (U.S. and Canada
